Zydus Lifesciences increased its share buyback price to ₹1,260. HG Infra secured a 35-year Transmission Service Provider contract expected to yield ₹115 crore annually. Other companies reported mixed Q4 results.
Zydus Lifesciences has revised its share buyback strategy, increasing the buyback price to ₹1,260 per share while reducing the total number of shares to 0.87 crore. HG Infra has been awarded a significant 35-year Transmission Service Provider contract, projected to generate ₹115 crore in revenue annually. Reader Takeaway: Buyback price hike signals confidence; long-term contract offers stable revenue. ## What just happened Zydus Lifesciences' board approved a revised buyback offer, increasing the price per share to ₹1,260. Concurrently, the total number of shares to be bought back has been reduced to 87 lakh. HG Infra has secured a new contract to act as a Transmission Service Provider for 35 years. This contract is expected to bring in ₹115 crore each year. ## Why this matters For Zydus Lifesciences, the increased buyback price suggests management's belief that the company's shares are undervalued at current market prices, potentially supporting the stock. For HG Infra, the long-term nature of the contract provides significant revenue visibility and stability, which is a positive indicator for future earnings. ## The backstory Praj Industries reported net sales of ₹845 crore and a net profit of ₹12 crore for Q4FY26. Bata India's net profit stood at ₹2 crore, impacted by one-time costs. Relaxo Footwears saw net sales of ₹751 crore, indicating volume-led growth. HG Infra's Q4 revenue was reported at ₹1,354 crore. ## What changes now The revised buyback by Zydus Lifesciences indicates a shift in capital allocation strategy. HG Infra's new contract adds a substantial, long-term revenue stream to its order book, enhancing its operational outlook. ## Risks to watch Investors should watch for any further changes in Zydus Lifesciences' buyback terms or market reaction. For HG Infra, successful execution of the new contract and managing operational costs will be key. ## Peer comparison While Praj Industries and Bata India faced performance challenges in Q4, HG Infra's new contract win positions it strongly. Zydus Lifesciences' buyback adjustment needs to be viewed against its overall financial health and industry peers. ## Context metrics (time-bound) Praj Industries' Q4FY26 net sales were ₹845 crore, with a net profit of ₹12 crore. Bata India's Q4FY26 net profit was ₹2 crore. Relaxo Footwears' Q4FY26 net sales were ₹751 crore. HG Infra's Q4 revenue was ₹1,354 crore. ## What to track next Investors will be looking for management commentary from Zydus Lifesciences regarding the buyback rationale and future capital allocation. For HG Infra, updates on the commencement and execution of the new transmission contract will be crucial.
Get stock alerts instantly on WhatsApp
Quarterly results, bulk deals, concall updates and major announcements delivered in real time.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.
